BNP Paribas Financial Markets Has $111.66 Million Stock Holdings in Becton, Dickinson and Company $BDX

BNP Paribas Financial Markets grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 88.3% during the fourth quarter, Holdings Channel reports. The firm owned 575,371 shares of the medical instruments supplier’s stock after acquiring an additional 269,787 shares during the quarter. BNP Paribas Financial Markets’ holdings in Becton, Dickinson and Company were worth $111,662,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BDX. Wellington Management Group LLP lifted its stake in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after purchasing an additional 5,174,944 shares during the period. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after purchasing an additional 4,137,888 shares during the period. Norges Bank acquired a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $734,321,000. Finally, First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on BDX. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a report on Friday, April 17th. Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. TD Cowen reduced their price target on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Stifel Nicolaus reduced their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $183.64.

Becton, Dickinson and Company Price Performance

BDX opened at $147.13 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The company has a market capitalization of $40.54 billion, a price-to-earnings ratio of 37.25, a P/E/G ratio of 10.42 and a beta of 0.22. The firm’s fifty day moving average price is $151.63 and its two-hundred day moving average price is $176.99. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.